CAPR vs. ATRC, AHCO, NEOG, PAHC, BLFS, INMD, KMTS, OMI, CBLL, and MRVI
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include AtriCure (ATRC), AdaptHealth (AHCO), Neogen (NEOG), Phibro Animal Health (PAHC), BioLife Solutions (BLFS), InMode (INMD), Kestra Medical Technologies (KMTS), Owens & Minor (OMI), CeriBell (CBLL), and Maravai LifeSciences (MRVI). These companies are all part of the "med products" industry.
Capricor Therapeutics vs. Its Competitors
AtriCure (NASDAQ:ATRC) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.
AtriCure has a net margin of -7.95% compared to Capricor Therapeutics' net margin of -181.71%. AtriCure's return on equity of -5.68% beat Capricor Therapeutics' return on equity.
AtriCure currently has a consensus price target of $50.67, suggesting a potential upside of 59.43%. Capricor Therapeutics has a consensus price target of $32.22, suggesting a potential upside of 219.19%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than AtriCure.
In the previous week, Capricor Therapeutics had 9 more articles in the media than AtriCure. MarketBeat recorded 12 mentions for Capricor Therapeutics and 3 mentions for AtriCure. Capricor Therapeutics' average media sentiment score of 0.66 beat AtriCure's score of 0.34 indicating that Capricor Therapeutics is being referred to more favorably in the news media.
Capricor Therapeutics has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.
AtriCure has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
99.1% of AtriCure shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 3.5% of AtriCure shares are held by insiders. Comparatively, 10.5% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Capricor Therapeutics beats AtriCure on 9 of the 17 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CAPR) was last updated on 7/5/2025 by MarketBeat.com Staff
